What was the primary driver of Cencora's revenue growth in this quarter?

The primary driver of Cencora's revenue growth was the Pharmaceutical Distribution segment, which saw an 11% increase in operating revenue. This was supported by increased business from institutional customers and growth in the specialty pharmaceutical sector.

What factors contributed to the increase in net income despite a lower gross profit margin?

The increase in net income was primarily driven by a significant reduction in distribution, selling, and administrative (DS&A) expenses as a percentage of operating revenue. Operational efficiencies, merger integration efforts, and a reduction in the allowance for doubtful accounts contributed to these savings, more than offsetting the decline in gross profit margin.

What are the key risks facing Cencora in the near future?

Two major risks identified are the potential loss of the U.S. Department of Veterans Affairs (VA) as a primary distributor, a decision the company is contesting, and the potential loss of business from AdvancePCS if its acquisition by Caremark proceeds. These represent significant portions of the company's revenue.

How is Cencora managing its liquidity and debt?

Cencora maintains strong liquidity with approximately $1.99 billion in additional availability under its revolving credit and receivables securitization facilities. The company has a mix of fixed-rate and variable-rate debt and continues to generate sufficient cash flow from operations to meet its working capital, capital expenditure, and debt repayment needs.

COR 10-Q Quarterly Report Q1 FY2004 — Revenue, Net Income, EPS

Summary

Cencora, Inc. (formerly AmerisourceBergen Corporation) reported its financial results for the quarter ended December 31, 2003. The company demonstrated revenue growth, with total revenue increasing by 10% year-over-year to $13.36 billion. This growth was primarily driven by an 11% increase in the Pharmaceutical Distribution segment, while the PharMerica segment remained relatively flat. Net income saw a significant increase of 17% to $108.5 million, resulting in diluted earnings per share of $0.94, up from $0.84 in the prior year. This improved profitability was supported by operational efficiencies and a reduction in distribution, selling, and administrative expenses as a percentage of revenue, which helped offset a decline in gross profit margin. Investors should note the company is managing significant integration efforts related to its 2001 merger, including facility consolidations. Significant upcoming challenges include the potential loss of the U.S. Department of Veterans Affairs (VA) as a primary distributor and the potential loss of business from AdvancePCS following its acquisition. The company is actively contesting the VA decision. Despite these headwinds, the company's liquidity remains strong with substantial availability under its credit facilities.

Key Highlights

1Total revenue increased 10% to $13.36 billion for the quarter ended December 31, 2003.
2Net income rose 17% to $108.5 million, with diluted EPS growing 12% to $0.94.
3Distribution, selling, and administrative (DS&A) expenses as a percentage of revenue decreased to 2.57% from 3.02% in the prior year.
4Gross profit margin declined to 4.30% of operating revenue from 4.69% in the prior year, impacted by customer mix and pricing pressures.
5The company is actively managing merger integration efforts, including facility consolidations, with ongoing costs and anticipated synergies.
6Potential significant business losses are anticipated from the VA contract and the AdvancePCS customer.
7Liquidity is supported by substantial availability under revolving credit and securitization facilities totaling $1.99 billion.

Cencora, Inc. Quarterly Report for Q1 Ended Dec 31, 2003

Summary

Key Highlights

Frequently Asked Questions